Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The National Cancer Institute is seeking grant applications for the Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research program. This initiative focuses on funding early-stage, proof-of-concept, and pilot studies to test the technical feasibility of innovative tools, assays, platforms, or instruments. The goal is to develop technologies that significantly enhance cancer research and clinical care, specifically in areas such as cancer biology, early detection, screening, diagnosis, treatment, and epidemiology. Eligible projects must demonstrate high technical innovation and the ability to improve the measurement, analysis, or modeling of cancer-related systems. This includes advancements in multi-omic profiling, imaging, sensing, immuno-engineering, and biospecimen processing. While the developed technologies may have broad applications, the proposal must remain focused on cancer. This opportunity is part of the broader Innovative Molecular Analysis Technologies program managed by the National Institutes of Health.
General Info
Place of Performance
Not specifiedSet-Aside
Documents
0AI Contract Breakdown
Uniform Contract FormatNo documents to break down
The breakdown needs solicitation documents. None were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing to develop innovative technologies for cancer research or clinical care. The emphasis of this NOFO is on early-stage projects proposing proof-of-concept/pilot studies to test the technical feasibility of the proposed method, tool, assay, platform, or instrument.
Well-suited applications must offer a high degree of technical innovation and the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, cancer control, and/or epidemiology. Projects that are in-scope include technologies with new or significantly improved technical capabilities to measure, analyze, model, or interrogate cancer-related systems. These may include, but are not limited to, advanced molecular and cellular analysis platforms, multi-omic and spatial profiling methods, imaging and sensing technologies, immuno-engineering approaches, and innovations in biospecimen processing, modeling, and quality assessment. Technologies proposed for development may have potential for widespread applicability but must be focused in this proposal on cancer applications.
This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Similar Contracts
Same NAICS industry code
More opportunities from Department Of Health And Human Services → National Institutes Of Health
Same awarding agency
Earlier notices in this NAICS code
Posted before this notice, open and closed
Ready to Pursue This Opportunity?
Get AI-powered intelligence on this solicitation and the ones like it
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 750+ contractors already using CLEATUS
